|
May 14
|
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
Apr 25
|
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
|
|
Apr 12
|
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
|
|
Apr 11
|
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
|
|
Apr 9
|
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
|
|
Apr 4
|
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
|
|
Apr 4
|
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
|
Nov 28
|
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
|
|
Nov 4
|
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
|
|
Nov 3
|
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
|
Aug 10
|
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|